Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday
We recently compiled a list of the 10 Firms Buck Market Bloodbath on Monday. In this article, we are going to take a look at ...
Protagonist Therapeutics price target raised to $72 from $62 at BMO Capital
BMO Capital raised the firm’s price target on Protagonist Therapeutics (PTGX) to $72 from $62 and keeps an Outperform rating on the shares.
Protagonist reports top line results from Phase 2b study of icotrokinra
Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...